Bicara Therapeutics Inc.’s (NASDAQ:BCAX) Lock-Up Period Set To Expire on March 12th

Bicara Therapeutics’ (NASDAQ:BCAX) lock-up period is set to end on Wednesday, March 12th. Bicara Therapeutics had issued 17,500,000 shares in its IPO on September 13th. The total size of the offering was $315,000,000 based on an initial share price of $18.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on BCAX. Rodman & Renshaw initiated coverage on Bicara Therapeutics in a research note on Tuesday, November 5th. They set a “buy” rating and a $48.00 target price for the company. RODMAN&RENSHAW raised shares of Bicara Therapeutics to a “strong-buy” rating in a report on Tuesday, November 5th. Wedbush restated an “outperform” rating and issued a $31.00 target price on shares of Bicara Therapeutics in a report on Wednesday, February 12th. Finally, HC Wainwright lifted their price target on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, January 27th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $41.20.

Bicara Therapeutics Stock Performance

Shares of BCAX opened at $13.67 on Wednesday. The business’s 50 day simple moving average is $13.71. Bicara Therapeutics has a 12-month low of $11.10 and a 12-month high of $28.09.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of BCAX. First Turn Management LLC purchased a new stake in shares of Bicara Therapeutics in the third quarter valued at about $14,324,000. The Manufacturers Life Insurance Company acquired a new position in Bicara Therapeutics in the 3rd quarter valued at about $582,000. FMR LLC purchased a new stake in Bicara Therapeutics during the 3rd quarter valued at approximately $57,913,000. Walleye Capital LLC acquired a new stake in Bicara Therapeutics during the 3rd quarter worth approximately $809,000. Finally, Vestal Point Capital LP purchased a new position in shares of Bicara Therapeutics in the 3rd quarter valued at approximately $10,825,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.